- $17.39m
- $13.67m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.65 | ||
| Price to Tang. Book | 5.65 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -182.98% | ||
| Return on Equity | -216.99% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Directors
- Russell Greig NEC (68)
- Jonathan Solomon CEO (44)
- Marina Wolfson SVP (37)
- Merav Bassan OTH (55)
- Assaf Oron OTH (46)
- Sailaja Puttagunta OTH (52)
- Gbola Amusa IND (47)
- Jonas Grossman IND (47)
- Alan Moses IND (73)
- Paul Sekhri IND (63)
- Lynne Sullivan IND (55)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 1st, 2017
- Public Since
- December 18th, 2018
- No. of Employees
- 58
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NYSE MKT- Shares in Issue
- 55,220,077
- Address
- 22 Einstein St., Floor 4, NESS-ZIONA, 7414003
- Web
- https://www.biomx.com/
- Phone
- +1 6464659000
- Contact
- Anat Primovich
- Auditors
- Kesselman & Kesselman
Upcoming Events for PHGE
Biomx Inc Annual Shareholders Meeting
Q2 2024 Biomx Inc Earnings Release
Similar to PHGE
Actinium Pharmaceuticals
NYSE MKT
Aeon Biopharma
NYSE MKT
AIM ImmunoTech
NYSE MKT
Ampio Pharmaceuticals
NYSE MKT
Armata Pharmaceuticals
NYSE MKT
FAQ
What is the Biomx share price?
As of Today at 19:04 UTC, shares in Biomx are trading at $0.32. This share price information is delayed by 15 minutes.
How has the Biomx share price performed this year?
Shares in Biomx last closed at $0.32 and the price had moved by +13.15% over the past 365 days. In terms of relative price strength the Biomx share price has underperformed the S&P500 Index by -8.62% over the past year.
What are the analyst and broker recommendations for Biomx?
There is no consensus recommendation for this security.
What is the Biomx dividend yield?
Biomx does not currently pay a dividend.
Does Biomx pay a dividend?
Biomx does not currently pay a dividend.
When does Biomx next pay dividends?
Biomx does not currently pay a dividend.
How do I buy Biomx shares?
To buy shares in Biomx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biomx?
As of the previous close price of $0.32, shares in Biomx had a market capitalisation of $17.39m.
Where are Biomx shares listed?
Here are the trading details for Biomx:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: PHGE
What kind of share is Biomx?
Based on an overall assessment of its quality, value and momentum Biomx is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biomx share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Biomx share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biomx. Over the past six months, its share price has underperformed the S&P500 Index by -17.67%.
As of the last closing price of $0.32, shares in Biomx were trading -5.96% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biomx PE Ratio?
The Biomx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biomx?
Biomx's management team is headed by:
- Russell Greig - NEC
- Jonathan Solomon - CEO
- Marina Wolfson - SVP
- Merav Bassan - OTH
- Assaf Oron - OTH
- Sailaja Puttagunta - OTH
- Gbola Amusa - IND
- Jonas Grossman - IND
- Alan Moses - IND
- Paul Sekhri - IND
- Lynne Sullivan - IND